Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Anita Karimi, Christina Bogdani, Elisabeth O’Dwyer, Despina Siolas
Abstract
Abstract Pancreatic neuroendocrine tumors (pNETs) often overexpress somatostatin receptor type 2 (SSTR2), making them ideal targets for theranostics, which integrates molecular imaging with targeted radionuclide therapy. 177 Lu-DOTATATE significantly extends progression-free survival (22.8 vs. 8.5 months) compared to octreotide LAR. Despite these advances, challenges remain, including treatment resistance and long-term toxicities. In this review, we explore advancements in specialized imaging techniques, rationale combination strategies, and exploring next-generation radiopharmaceuticals.
Topics & Concepts
Neuroendocrine tumorsSomatostatin receptorRadionuclide therapyOctreotideSomatostatin receptor 2MedicineSomatostatinCancer researchMolecular imagingInternal medicineBiologyIn vivoBiotechnologyNeuroendocrine Tumor Research AdvancesNeuroblastoma Research and TreatmentsLung Cancer Research Studies